Market size by 5 key segments
Key untapped opportunities
Addressable market framework
Patient journey context
Created specifically for executives and managers evaluating hearing healthcare investments, the report combines a rigorous statistical overview of the hearing loss market size with strategic recommendations. The report is unmatched by providing a framework for the addressable market and identifying untapped segment opportunities. Lead author Nancy M. Williams, President of Auditory Insight, advises drug therapy and device companies on how to transform hearing healthcare.
All data for 2020 unless specified otherwise
- Overall hearing loss market size and segmentation variables
- Key findings for the five hearing loss segmentation variables
- Definition of key terms
Overview of Hearing Loss
- Auditory Insight proprietary framework for the patient journey with hearing aids
- Measuring hearing loss with pure tone hearing test
- Potential new measures of hearing loss
Overall Market Size and Growth of Population with Hearing Loss
- Market size of adults ≥20 with hearing loss, 2020 vs. 2030
- Two key measures of consumer-patient behavior in hearing loss treatment
- Total hearing loss market segmented by two key behavioral measures for adults ≥50
Segmentation Variable (SV) #1
- Clinical definition of hearing loss by SV #1
- Interventions for hearing loss by SV #1
- Hearing loss market size and prevalence by SV #1 for adults ≥20
- Hearing loss market size and prevalence by SV #1 for adults ≥20, 2020 vs. 2030
- Total hearing loss market segmented by two key behavioral measures and SV #1 for adults ≥50
- The effect of perception on hearing loss for adults ≥60
- Hearing loss market segmented by perception of hearing loss and SV #1 for adults ≥60
Segmentation Variable (SV) #2
- Hearing loss market size and prevalence by SV #2 for adults ≥20
- Hearing loss market size and prevalence by SV #1 and SV #2 for adults ≥50
- Hearing loss market size and prevalence by SV #1 and SV #2 for adults ≥60, 2020 vs. 2030
- Total hearing loss market segmented by two key behavioral measures and SV #1 and SV #2 for adults ≥60
- Hearing loss market segmented by perception of hearing loss and SV #2 for adults ≥60
Segmentation Variable (SV) #3
- Hearing loss market size and prevalence by SV #3 for adults ≥60
- Total hearing loss market segmented by one key behavioral measure and SV #3 for adults ≥55
- Hearing loss market segmented by perception of hearing loss and SV #3 for adults ≥60
Segmentation Variable (SV) #4
- Hearing loss market size and prevalence by SV #2 and SV #4 for adults ≥20
- Total hearing loss market segmented by one key behavioral measure and SV #4 for adults ≥55
Segmentation Variable (SV) #5
- Hearing loss market size and prevalence by SV #2 and SV #5 for adults ≥20
- Total hearing loss market segmented by one key behavioral measure and SV #5 for adults ≥50
Framework for Calculating Addressable Market Size
- Framework for calculating addressable market for hearing loss population
- Strengths and limitations of the addressable market framework
- Application of framework for calculating addressable market for hearing loss population ≥50
- Overview of key insights
- The composite person with hearing loss
- Untapped opportunities from analyzing the composite person with hearing loss
- Untapped opportunity #1
- Untapped opportunity #2
- Untapped opportunity #3
- Summary of Auditory Insight recommendations
- Options for customizing this study
- Overall study approach
- NHANES data set characterization
- Key definitions and measurements
- Report sources by study section
The most comprehensive, strategically focused, and analytically-grounded study available on the hearing loss market.
- Commitment to the highest quality insights. Analytical depth, strategic insights, and integrated viewpoint from Auditory Insight’s exclusive focus on the hearing healthcare industry.
- Original biostatistical analysis on consumer-patient behavior. Previously unpublished analysis of key behavioral drivers for people seeking treatment for hearing loss.
- Consistent data source to enable comparisons. Consistent use of National Health and Nutrition Examination Survey (NHANES), facilitating comparative analysis for market size overall and for the five key segments.
- Current 2020 data year for accurate forecasting. Superseding other reports which use a jumble of data years and older studies; study baselines the market size in 2020 and provides forecasts for 2030.
- Product independent. Encompassing the hearing loss market as a whole, rather than zeroing in on the hearing aid industry, providing market size data for drug therapy and hearable companies with new products.
- Addressable market framework. An actionable framework for companies to calculate the addressable market based on the total opportunity and the company’s particular device or drug therapy.
- Rigorous segmentation scheme. Identification and explanation of the top five segmentation variables for the hearing loss market, as well as the market size for each segment.
- Strategic implications for investment. Four key strategic implications of the market size data, including two untapped high-potential opportunities.
- Patient journey context. Overview of the five key stages of the patient journey with hearing aids, as well as the primary consumer-patient activities for each stage, an important foundation for understanding the market.
- Insider perspective on hearing loss. Lead author Nancy M. Williams is not only a strategic advisor in hearing healthcare but also has lived with hearing loss all of her life and is an internationally recognized hearing health advocate.
This study integrates, interprets, and analyzes data from the National Health Examination and Nutrition Survey (NHANES), to create a unified viewpoint on hearing loss market size, segmentation variables, and untapped opportunities.
The data from NHANES, a major program of the National Center for Health Statistics, is unique, in that it combines interviews and physical examinations, including an audiogram to measure hearing loss.
To create the core data set for this study, Auditory Insight commissioned a proprietary study of NHANES data in December 2019 from a leading and internationally-recognized academic in epidemiology and biostatistics hearing loss research.
To supplement the core data set, in November 2019, Auditory Insight conducted a meta-analysis of the latest peer-reviewed articles published in leading medical journals and authored by renowned academics in the hearing healthcare field, on the topics of the market size, segmentation variables, and consumer-patient behavior in seeking treatment for hearing loss.
Combining the Auditory Insight proprietary analysis and the meta-analysis results in a consistent data set that is the most current in the marketplace, enabling accurate forecasting and comparisons across segmentation variables.
Nancy M. Williams, President and Founder, Auditory Insight
Nancy M. Williams advises leaders of pharma and device companies how to transform hearing healthcare with breakthrough engagement strategies and innovative models of care, with the objective of driving patient adoption and revenue growth.
Nancy leverages her expertise in new market development, patient engagement, and consumer insight, as well as her experiences as a hearing health advocate and person with hearing loss, to develop visionary solutions for companies solving hearing loss. Adept at breaking through conventional molds to create value, she has generated over $120M in new revenue in public and privately-held companies.
Her articles in publications such as Hearing Journal, MedCity News, and Hearing Loss Magazine are widely read by consumers and hearing healthcare executives alike. She served on the Board of the Hearing Health Foundation for four years.
Nancy holds an MBA from Harvard Business School and a BA from Stanford University in Quantitative Economics, both with distinction.
Tori Tan, Consulting Analyst, Auditory Insight
Tori Tan serves as a consulting analyst with Auditory Insight. She graduates with a Masters of Public Health (MPH) from the Yale School of Public Health with a concentration in Health Care Management in May 2020. Past work experience includes Deloitte Consulting. She holds a B.A. in Molecular Cell Biology from the University of California, Berkeley.